This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Able and willing to provide a written informed consent.
2. Blood pressure as defined in the protocol.
3. Male or female，aged 18 to 55 years (inclusive).
4. Meet the weight standard.
Exclusion Criteria:
1. Known history or current clinically significant disease.
2. Protocol-defined risk factors for disease.
3. Participated in clinical trials of other drugs or medical devices.
4. Pregnant or nursing women.
Primary outcome measure(s)
Adverse events (AEs) — Approximately 16 weeks.
Trial sites (1)
Facility
City
Region
Status
Beijing Anzhen Hospital Capital Medical University
Beijing
Beijing Municipality
More Beijing Suncadia Pharmaceuticals Co., Ltd trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.